New drug duo aims to hunt down Cancer's last traces
NCT ID NCT07071961
Summary
This study is testing whether a combination of two drugs, regorafenib and lorigerlimab, can clear tiny traces of cancer left in the blood after standard treatment for colorectal cancer. The goal is to see if this treatment can prevent the cancer from coming back in patients who show no signs of disease on scans but have molecular evidence of remaining cancer. The trial is currently suspended and was enrolling a small group of high-risk patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.